Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer

Clinical Trial ID NCT00624182

Rank	Title	Journal	Year	PubWeight™‹?›
1	Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.	Nat Med	1998	11.03
2	Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.	Int J Cancer	1999	3.19
3	Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma.	Hepatology	2005	1.43
4	Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy.	Cancer Sci	2007	1.35
5	Trial watch: Peptide vaccines in cancer therapy.	Oncoimmunology	2012	1.17
6	Trial Watch: Peptide-based anticancer vaccines.	Oncoimmunology	2015	1.13
7	DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese.	Tissue Antigens	1996	1.01
8	Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro.	J Immunol	2005	1.00
9	Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells.	J Immunother	2005	0.90
10	Antigen-specific vaccines for cancer treatment.	Hum Vaccin Immunother	2014	0.89